Merck(US:MRK) Financial Modeling Prep·2026-01-20 18:09Core Viewpoint - Merck & Co., Inc. is making significant advancements in cancer treatment through its collaboration with Moderna, particularly with a promising cancer vaccine aimed at melanoma, which has shown a substantial reduction in relapse or death risk among patients [3][4][6]. Group 1: Company Overview - Merck & Co., Inc. is a global healthcare company known for its innovative research in oncology, vaccines, and infectious diseases [1]. - The company faces competition from major pharmaceutical players such as Pfizer and Johnson & Johnson [1]. Group 2: Stock Performance and Analyst Ratings - Cowen & Co. has maintained a "Hold" rating for Merck, with the stock currently priced at $108.83, reflecting a 1.93% decrease [2][5]. - TD Cowen has raised Merck's price target from $100 to $120, indicating optimism about the company's future performance [2][6]. - Merck's market capitalization is approximately $271.83 billion, with a trading volume of 10.72 million shares, suggesting active investor interest [5]. Group 3: Cancer Vaccine Study Results - Merck, in collaboration with Moderna, reported promising results from a cancer vaccine study, showing a 49% reduction in the risk of recurrence or death for melanoma patients [3][4][6]. - The combination of the experimental vaccine with Merck's Keytruda demonstrated sustained benefits over five years, highlighting its potential impact on serious skin cancer treatment [4][6].